Group items matching

in title, tags, annotations or url

The global market for chronic kidney disease drugs is expected to witness single-digit growth during 2019-2025. The drug pipeline of chronic kidney disease looks promising with novel therapeutic approaches, such as cell therapy, likely to enhance the market growth opportunities. However, the competition from biosimilars and complex drug development processes are impeding the market growth. Over the period, extensive research is being done to fill the unmet needs' gap. The advances in the arena of regenerative treatment have come up with budding advancement of cell therapies that help regeneration and repairing of the kidneys. Cell therapy is proficient of refining the fundamental functioning capability of the kidney. Uncontrolled high blood pressure and diabetes are the leading causes of kidney failure globally.

E-pharmacy, a digital platform also known as internet pharmacy or online pharmacy, has emerged as an escape route to longstanding queues at pharmacy stores across almost all regions of the world, especially during the Covid-19 health crisis realm. They have long been recognised to act promptly in public health response, like ensuring an effective medicine supply system, resolving and monitoring drug shortage issues, educating about the proper use of PPE, promoting remote pharmacy services, and conducting drug evaluation and active surveillance. These factors will support in easing the load on healthcare facilities during the ongoing pandemic, eventually adding value to patients and the healthcare system. Overall, the e-pharmacy market size is expanding in terms of valuation on the back of regulations and standards laid by the respective governments. As per a recent study by Global Market Insights, the Global e-pharmacy industry accounted for a business share of $68 billion in 2021 with an anticipated growth rate of 16.8 per cent through 2028.

Following discussions with Community Pharmacy Scotland, the Scottish government has agreed to a six per cent rise in the global fund allocation for community pharmacies in 2023-24, bringing the total remuneration to approximately £219.5 million. A finalised agreement has been reached with Community Pharmacy Scotland for a one-year funding package for the financial year 2023-24, as stated in a Scottish government circular distributed to community pharmacy contractors and NHS Boards on August 4. The circular said this settlement will lead to the most substantial increment ever approved for the community pharmacy network. "The global sum remuneration will be £219.533 million, signifying a 6 per cent increase from the previous year and setting the groundwork for 2024/25," stated Professor Alison Strath, Chief Pharmaceutical Officer for Scotland, in the document. "The guaranteed income from the drug tariff will remain at £80 million for the financial year, without yearly changes."

Minimal Access Cardiac Surgery workshop was published in leading newspapers in Hyderabad held at Global Hospitals.

Minimal Access Cardiac Surgery workshop was published in leading newspapers in Hyderabad held at Global Hospitals.

Minimal Access Cardiac Surgery workshop was published in leading newspapers in Hyderabad held at Global Hospitals.

Market Industry Reports (MIR) has published a new report titled "IV Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2030." According to the report, the Global IV Equipment market is estimated to be around US$ 10.0 Bn in 2017. It is anticipated to grow at a substantial CAGR from 2019 to 2030.

Global Vascular Graft Market Size, Status and Forecast 2025, Our objective is to provide strategic key market information like Sales Volume, Market Share, market size estimations, CAGR, Competition by Players/Suppliers, Type and Application, next 5-year market forecast & Industry trends etc. The target geography in this research report is USA, Europe, Asia-Pacific, Middle East and Africa.

The Veterinary Software Report Provide SWOT analysis to understand Strengths, Weaknesses, Opportunities, and Threats of the Veterinary Software industry along with competitive Analysis. Along with, analysis of upstream raw materials and downstream consumers are also conducted in Veterinary Software research study. Global Veterinary Software market influences various other factors such as Globalization, improvements in trade and income, and commercialization to enhance extensive growth.

The Global Wound Debridement Market Research Report 2018 gives an in-depth valuation of the Wound Debridement that includes technologies, key trends, market share, size, challenges, opportunities, future forecast, value chain, and strategies. The Research report gives a complete overview of the market and contains a Future trend, Current Growth Factors. The study is segmented by products type, application/end-users.

The global hemoglobinopathies market size is expected to reach USD 15.7 billion by 2028, according to a new report

The global end stage renal disease market size was valued at USD 74.5 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 12.7% from 2021 to 2028

The global pharmacovigilance market size was valued at USD 6.33 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 11.5% from 2021 to 2028.

Global drug discovery services market will continue to grow, owing to upsurge in externalization of R&D activities, rising expenditure on R&D, and increasing incidence of chronic diseases. Expiration of patents boosting the demand for drug discovery and the introduction of innovative drug discovery technologies are projected to support the market growth during the forecast period 2019-2025. The Global drug discovery services market, by type, is segmented into medicinal chemistry services, biology services, and pharmacokinetics and drug metabolism. Among these, the medicinal chemistry services segment accounted for the largest share in 2018 and is expected to grow at a high-double-digit CAGR by 2025. Increasing tendency of pharma companies to externalize discovery & development services, upsurge in the number of drug discovery & development activities, and growing R&D expenditure are the key factors driving the growth of the segment.

Infoholic's market research report predicts that the global leukemia therapeutics market will grow at a CAGR of 6.2% during the forecast period 2019-2025. Leukemia refers to the group of blood cancer that usually develops in the bone marrow, resulting in the formation of abnormal blood cells. Leukemia is subdivided into lymphoblastic or lymphocytic leukemias and myeloid or myelogenous leukemias that include acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). The report provides complete details about the sub-segment of the global leukemia therapeutics market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.

The global medical imaging market size was valued at USD 15.9 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 5.2% from 2021 to 2028.

US pharmaceutical giant Johnson & Johnson on Friday (November 12) announced plans to break up into two listed companies, separating its consumer health arm that sells Band-Aids and Tylenol from its pharmaceutical division. Johnson & Johnson said in a statement it will create "two global leaders that are better positioned to deliver improved health outcomes for patients and consumers through innovation." It plans to complete the separation in 18-24 months, creating two publicly traded companies. CEO Alex Gorsky said the decision was made following a "comprehensive review." The board and management believe the split is "the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals, create opportunities for our talented global team, drive profitable growth, and -- most importantly -improve healthcare outcomes for people around the world," he said.

The issues related to race and ethnicity are common across the sectors, but the problem is not unsolvable, said panelists in a discussion on Race, Identity and Belonging In The Workplace, held during the Pharmacy Business Diversity Conference on Thursday (December 9). Creating safe and comfortable spaces and allowing authentic conversations is a precursor to resolving this big challenge, said Zaheer Ahmad MBE, global head of Inclusion and Diversity at GSK Consumer Healthcare. The session, moderated by the conference chair BBC presenter Clive Myrie, also had Asif Sadiq MBE, senior vice president at WarnerMedia for Equity and Inclusion, International, and Sathya Bala, founder & CEO of True Change and My Skin My Story, a growing global community for women of colour. Ahmad said encouraging open conversations is important as there is great discomfort and stigma attached to talking about it, and many times senior leaders fall short in their efforts not because they have racist views or they don't believe in advancing race and ethnicity, but because they are not aware.

The Association of the British Pharmaceutical Industry (ABPI) has welcomed the National Institute for Health and Care Excellence's leadership in introducing a new approach to the evaluation of antibiotics. On Tuesday (12 April), NICE published a draft guidance to tackle antimicrobial resistance under which two new antimicrobial drugs - cefiderocol and ceftazidime-avibactam - became the first to be made available as part of the UK's innovative subscription-style payment model. Commenting on the announcement of the new draft guidance, Richard Torbett, chief executive of the ABPI, said: "This is an important milestone in the UK's global leadership on AMR. Antibiotics underpin modern medicine, but the increasing threat of antibiotic resistance remains one of the biggest global health challenges we face. "To tackle this, it is critical that the appropriate frameworks are in place for companies to invest the billions of pounds required to discover the new antibiotics needed for patients.

Global demand for Pfizer's oral Covid-19 antiviral treatment Paxlovid has been unexpectedly low due to complicated eligibility requirements, reduced testing, and potential for drug interactions, according to a media report. Demand also has been hampered by the perception that Omicron infections are not that severe. Paxlovid was expected to be a major tool in the fight against Covid after it reduced hospitalizations or deaths in high-risk patients by around 90 per cent in a clinical trial. Thousands of people still die from Covid-19 every week, even as Global infections are far off their peak. And there are only a few proven antiviral treatments, of which Paxlovid is the most attractive. The others are Merck & Co's far less effective rival pill molnupiravir, and Gilead Sciences' intravenous remdesivir.

Wockhardt UK managing director Ravindra Limaye has been chosen for honorary British awards given to foreign nationals. Limaye gets the Order of the British Empire (OBE) honour for his contribution to health, particularly during the Covid-19 pandemic. The honours were announced on Thursday (13). Limaye has been the chief executive of the UK arm of the Mumbai-based pharma and biotech company Wockhardt since 2019. He previously worked for another Indian pharma company Biocon, overseeing its global commercial operations. He led the company's entry into global biosimilar markets and spearheaded its operations in the US.

Pharmanovia, a global pharmaceutical company has announced increased targets to divert 40 per cent of its air shipments to sea in 2023, and 75 per cent by the end of 2028. It has made the pledge as it revealed the significant progress made towards achieving its ambitious science-backed ESG initiatives in its new Sustainability Report. Its industry-leading air-to-sea pilot scheme, which focused on its Spain-to-Australia freight route, cut an estimated 470,000kg in potential CO2 emissions in 2022 - reducing Scope 3 upstream transport emissions by 18 per cent. This initiative demonstrates Pharmanovia's role as an industry leader on carbon reduction and follows a recent report which stated just 16 of 500 pharmaceutical companies measured their entire Scope 3 emissions. The new Sustainability Report reveals that the Scope 2 emissions decreasing by 13 per cent in 2022, due to lower direct electricity demand within the office space. The company's packaging audit seeing a 52 per cent increase in the percentage of products packed with at least one fully recyclable component, up from 12% in 2021 to 64 per cent in 2022 Strong progress in an initiative which saw Pharmanovia set ESG goals all employees across its global offices as part of annual performance awards. Employees achieved a 98 per cent completion rate of the compliance training, including ESG modules